Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

In vitro susceptibility testing and totally drug-resistant tuberculosis

Shashikant Srivastava, Carleton Sherman, Tawanda Gumbo
European Respiratory Journal 2013 42: 291-292; DOI: 10.1183/09031936.00205212
Shashikant Srivastava
1Dept of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Shashi.kant@utsouthwestern.edu
Carleton Sherman
1Dept of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tawanda Gumbo
1Dept of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
2Office of Global Health, University of Texas Southwestern Medical Center, Dallas, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

To the Editor:

We find the article by Migliori et al. [1], on extensively drug-resistant tuberculosis (XDR-TB), very informative and would like to commend them for the excellent meta-analysis. Without any doubt, XDR-TB is an extensive global problem; the use of the lower susceptibility breaking points that we recently suggested [2] mean that the burden of XDR-TB could be even higher. Although there are recent reports of “totally drug-resistant (TDR)” TB, the World Health Organization does not recognise this term [3]. There is already a social stigma attached to having TB in many parts of the world and a label of TDR poses further challenges for patients. Antibiotic susceptibility testing is ideal for all patients, and is even more of a requirement when a patient is not responding to the anti-TB therapy. Lessons from other infectious diseases suggest that an even better approach would be to record actual minimum inhibitory concentrations (MICs), but clearly these are difficult to perform for TB in many laboratories and need further standardisation. Management of TB always involves a combination therapy, whereas drug sensitivity is measured for a single drug and not for the combination of drugs used for the treatment. Therefore, there is a possibility that even though the bacteria is resistant to the drug in vitro, combination therapy may still work, as evidenced by the results of the present report [1], and another article by Udwadia and Vendoti [4]. This is because there could be a number of other factors beyond “resistance” or MIC that lead to the unfavourable response to the treatment. These include, but are not limited to, the interindividual differences in pharmacokinetics as well as genetic makeup of an individual [5]. While there is no quick measure to prevent the emergence of resistance, knowledge acquired from scientific research should be translated to develop new tools to improve patient care. We suggest that patients with suspected or confirmed XDR-TB should be subjected to therapeutic drug monitoring (TDM) to make sure that the desired drug concentration is achieved with the administration of the prescribed drug doses. For those drugs with a good therapeutic window, and for drugs without concentration driven toxicity, higher doses can then be administered. Such doses can also be customised to achieve concentrations above those that define drug resistance or above the MIC, a solution already applied to other bacterial infections. We recognise that TDM for treatment of TB is in its infancy, and is potentially costly in resource limited settings. Nevertheless, it is a logical solution for these resistance patterns that are clearly associated with high mortality, as shown by the analysis of Migliori et al. [1]. Although drug susceptibility testing provides valuable information on the resistance pattern and remains an important tool to design therapeutic regimens, we should not give up by labelling patients as having “totally” drug-resistant TB, but instead continue with the XDR-TB label.

Footnotes

  • Conflict of interest: None declared.

  • Received December 20, 2012.
  • Accepted January 14, 2013.
  • ©ERS 2013

References

  1. ↵
    1. Migliori GB,
    2. Sotgiu G,
    3. Gandhi NR,
    4. et al
    . Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J 2013; 42: 169–179.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Gumbo T
    . New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54: 1484–1491.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    World Health Organization. Drug-resistant tuberculosis. Frequently asked questions. www.who.int/tb/challenges/mdr/tdrfaqs/en/ Date last accessed: December 17, 2012. Date last updated: January 24, 2012..
  4. ↵
    1. Udwadia Z,
    2. Vendoti D
    . Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. J Epidemiol Community Health 2013; 67: 471–472.
    OpenUrlFREE Full Text
  5. ↵
    1. Srivastava S,
    2. Pasipanodya JG,
    3. Meek C,
    4. et al
    . Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951–1959.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 42 Issue 1 Table of Contents
European Respiratory Journal: 42 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In vitro susceptibility testing and totally drug-resistant tuberculosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
In vitro susceptibility testing and totally drug-resistant tuberculosis
Shashikant Srivastava, Carleton Sherman, Tawanda Gumbo
European Respiratory Journal Jul 2013, 42 (1) 291-292; DOI: 10.1183/09031936.00205212

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
In vitro susceptibility testing and totally drug-resistant tuberculosis
Shashikant Srivastava, Carleton Sherman, Tawanda Gumbo
European Respiratory Journal Jul 2013, 42 (1) 291-292; DOI: 10.1183/09031936.00205212
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endothelial to mesenchymal transition as novel feature of pulmonary fibrosis
  • Transitioning endothelial cells contribute to pulmonary fibrosis
  • Treatable traits in ILD: why not consider acute exacerbations?
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society